New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic ...

Few patients with MDS receive treatment with hypomethylating agents, with evidence of age-, sex-, and race-related disparities.

Researchers sought to determine whether elderly, fit patients with AML would respond to therapy with venetoclax plus modified intensive chemotherapy.

Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.